Navigation Links
MAP Pharmaceuticals to Present Data on LEVADEX™ at the 63rd Annual Meeting of the American Academy of Neurology

MOUNTAIN VIEW, Calif., Feb. 28, 2011 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that LEVADEX™ orally inhaled migraine therapy will be featured in one oral presentation and four poster presentations at the 63rd Annual Meeting of the American Academy of Neurology (AAN) in Honolulu, Hawaii April 9-16, 2011. A summary of the Company's AAN presentations is below, and the abstracts can be accessed at the AAN website at LEVADEX is an investigational acute therapy for migraine that has completed Phase 3 clinical development.Utility of LEVADEX (MAP0004) in Situations Where Early Intervention Paradigm Is Impractical Session Info: Platform Session: April 12, 2011, 3:00-4:30 p.m. HASTPresentation Info: April 12, 2011 at 3:45 p.m. HASTPresentation #: 004An Open-Label, 2-Period, Crossover Study Comparing the Pharmacokinetics and Tolerability of LEVADEX (MAP0004, Orally Inhaled DHE) and Intravenous DHE (DHE45®) in Smoking and Non-Smoking Adult VolunteersSession Info: Poster Session 3: April 12, 2011, 2:00-6:00 p.m. HASTPoster #: 028A Randomized, Double-Blind, Placebo Controlled, Three-Period Crossover Study Comparing the Acute Effects of LEVADEX (MAP0004, Orally Inhaled DHE) and Intravenous DHE on Pulmonary Arterial Systolic PressureSession Info: Poster Session 3: April 12, 2011, 2:00-6:30 p.m. HASTPoster #: 029The Major Metabolite of Dihydroergotamine (DHE) after Oral Inhalation and IV Administration Does Not Significantly Contribute to the Pharmacologic ActivitySession Info: Poster Session 5: April 13, 2011, 2:00-6:30 p.m. HASTPoster #: 272Migraine Recurrence Rates: Case for Standardization of the DefinitionSession Info: Poster Session 5: April 13, 2011, 2:00-6:30 p.m. HASTPoster #: 285About LEVADEX™ LEVADEX is an investigational acute therapy for migraine that has completed Phase 3 clinical development.  In the clinical trial, patients administered LEVADEX themselves using the proprietary TEMPO® inhaler.  LEVADEX contains a novel formulation of dihydroergotamine (DHE).  LEVADEX was evaluated in the efficacy portion of FREEDOM-301, MAP Pharmaceuticals' Phase 3 pivotal trial, which included 395 patients in the LEVADEX arm and 397 patients in the placebo arm.  In the Phase 3 trial, patients taking LEVADEX therapy had statistically significant improvement at two hours compared to patients on placebo for all four co-primary endpoints:

  • Pain relief: 58.7 percent of patients who received LEVADEX compared with 34.5 percent for placebo (p<0.0001);
  • Phonophobia free: 52.9 percent of patients who received LEVADEX compared with 33.8 percent for placebo (p<0.0001);
  • Photophobia free: 46.6 percent of patients who received LEVADEX compared with 27.2 percent for placebo (p<0.0001); and
  • Nausea free: 67.1 percent of patients who received LEVADEX compared with 58.7 percent for placebo (p=0.02).

  • The most common adverse event reported was medication aftertaste at six percent versus two percent for placebo. The next most common adverse event was nausea at five percent compared with two percent for placebo.  There were no decreases in lung function, as measured by spirometry, between the active and placebo groups. 

    About Migraine Common symptoms of migraine include recurrent headaches, nausea, vomiting, photophobia (sensitivity to light) and phonophobia (sensitivity to sound).  According to the National Headache Foundation, most migraines last between four and 24 hours, but some last as long as three days.  On average, migraine sufferers experience 1.5 migraine attacks monthly, although 25 percent of them experience one or more attacks weekly.  The economic burden of migraine remains substantial despite existing treatments, with the direct and indirect costs of migraine in the United States estimated at over $20 billion annually.

    About MAP Pharmaceuticals MAP Pharmaceuticals is an emerging biopharmaceutical company focused on developing and commercializing new therapies to address undermet patient needs in neurology. The Company is developing LEVADEX orally inhaled therapy for the potential treatment of migraine and has reported positive results from the efficacy portion of its Phase 3 trial of LEVADEX. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history.  Additional information about MAP Pharmaceuticals can be found at

    Forward-Looking StatementsIn addition to statements of historical facts or statements of current conditions, this press release contains forward-looking statements, including with respect to MAP Pharmaceuticals' LEVADEX product candidate. Actual results may differ materially from current expectations based on risks and uncertainties affecting the Company's business, including, without limitation, risks and uncertainties relating to the development and regulatory approval process for the Company's LEVADEX product candidate. The reader is cautioned not to unduly rely on the forward-looking statements contained in this press release. MAP Pharmaceuticals expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. Additional information on potential factors that could affect MAP Pharmaceuticals' results and other risks and uncertainties are detailed in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2010, available at   CONTACTS: Nicole Foderaro

    Lisa BorlandWCG

    MAP Pharmaceuticals, Inc.(415) 215-5643


    SOURCE MAP Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Savient Pharmaceuticals Announces U.S. Launch of KRYSTEXXA™; Reports Fourth Quarter and Year-End 2010 Financial Results
    2. Auxilium Pharmaceuticals to Present at the 2011 Citi Annual Global Healthcare Conference
    3. Cumberland Pharmaceuticals Appoints Tan Cheow Choon as Director of International Business
    4. Anadys Pharmaceuticals to Report Fourth Quarter and Year-end 2010 Financial Results
    5. UCLA and Sound Pharmaceuticals Identify a Key Hearing Regeneration Protein in the Human Inner Ear
    6. JHP Pharmaceuticals Enters Another Multi-Year Contract Manufacturing Agreement
    7. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Fourth Quarter and Full Year Financial Results
    8. Inovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference
    9. Jazz Pharmaceuticals to Present at the Citi 2011 Global Health Care Conference in New York on March 1
    10. Tarix Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Study of TXA127 Following Autologous Peripheral Blood Stem Cell Transplant
    11. Idenix Pharmaceuticals to Present at an Upcoming Investor Conference
    Post Your Comments:
    (Date:11/30/2015)... Connecticut , November 30, 2015 ... Kentucky Breast Care has entered into a multi-year ... healthcare practice. This will allow Kentucky Breast Care to ... offer exceptional care for their patients. --> ... Kentucky Breast Care has entered into a multi-year ...
    (Date:11/29/2015)... , Nov. 29, 2015   Royal Philips  (NYSE: ... radiology solutions at the 2015 Radiological Society of North ... at McCormick Place in Chicago . ... experience the company,s broad portfolio of integrated Diagnostic Imaging, ... to increase clinical performance, improve workflow and create a ...
    (Date:11/29/2015)...  The GE Health Cloud 1 was unveiled today ... North America (RSNA) meeting in ... new cloud ecosystem and its applications will connect radiologists and ... multidisciplinary teams – both inside and outside the hospital setting. ... GE. "As the digital industrial leader, we are betting big ...
    Breaking Medicine Technology:
    (Date:11/30/2015)... ... November 30, 2015 , ... Holcomb – Kreithen ... plastic surgery practices in Florida, is proud to announce that Dr. Joshua Kreithen, ... giant Ethicon Inc., a Johnson & Johnson Company. , Ethicon is a global ...
    (Date:11/30/2015)... EMIGSVILLE, PA (PRWEB) , ... November 30, 2015 ... ... (CCMS) software provider, has verified that their Vasont Universal Integrator (VUI) extension unites ... handle creating, editing, and managing content as a continuous process with the latest ...
    (Date:11/30/2015)... Maryland (PRWEB) , ... November 30, 2015 , ... ... interactions could be of critical importance to the medical schools of the future. ... exhibited its healthcare suite at the 2015 ChangeMedEd conference in Chicago, organized by ...
    (Date:11/30/2015)... ... 30, 2015 , ... Innovaacom, a leading provider of medical ... survey of educational needs for pharmacists worldwide. The poll of pharmacists in Europe, ... quality online and face-to-face education for pharmacists who are fast becoming the new ...
    (Date:11/30/2015)... ... November 30, 2015 , ... ... In 2016, expected coding changes are likely to include new codes for spine ... not easy to understand the effects of code changes in musculoskeletal, radiology and ...
    Breaking Medicine News(10 mins):